CELL THERAPEUTIC AGENT FOR CANCER TREATMENT AND COMBINATION THERAPY WITH SAME

Description

[Technical Field]

[0001] The present disclosure relates to a method for preparing cells for cancer treatment, an adjuvant for anti-cancer comprising cells prepared by the same, and a kit for cancer treatment.

[Background Art]

[0002] Millions of people around the world die from various types of cancer including bone cancer, bladder cancer, blood cancer (leukemia), brain cancer, breast cancer, colorectal cancer, cervical cancer, esophageal cancer, bowel cancer, kidney cancer, lung cancer, liver cancer, oral cancer, nasal cancer, neural cancer, ovarian cancer, pancreatic cancer, skin cancer, stomach cancer, prostate cancer, neck cancer, uterine cancer, and vaginal cancer. Over the years, several methods including radiation and chemotherapy have been used to treat cancer, but the number of cancer patients is still increasing. It has been widely reported that radiation and chemotherapy may cause toxicity related diseases and even some patients die. In addition, in the case of specific cancer, there is a problem in that malignant cells remain difficult to treat. As a result, it is required to extensively study physiology or phenotype of cancer cells to find a treatment method that selectively kills the cancer cells without causing adverse effects on the patient's healthy cells.

[0003] In particular, a brain tumor is a type of cancer that causes great damage to the brain and has a very low survival rate. Among conventional treatment methods for the brain tumor, extraction by surgical operation is the most effective treatment, but there are a number of cases in that the surgery is not possible depending on the type and location of the brain tumor, and the risk of postoperative complications is very high at the time of complete extraction. Further, since a brain-blood barrier (BBB) that inhibits drug penetration is present in the brain, in order to treat brain tumor by chemotherapy using an anti-cancer agent, it is required to administer a high concentration of anti-cancer agent as compared to other types of cancer, which causes serious side effects in other organs of the body. Therefore, there is a need for a novel adjuvant method, a therapeutic agent, and an adjuvant that are able to lower the dose of the anti-cancer agent by enhancing effects of the anti-cancer agent.

[0004] In addition, a gene therapy method is a method of directly introducing a gene that inhibits proliferation of cancer cells into the cancer cells. For gene introduction, a virus is mainly used, but since the virus itself does not have an ability to move to cancer, it is required to inject the virus surgically. However, it is practically impossible to inject the viruses into every microscopic tumor or cancer cells, and thus, there is a limitation in targeting the cancer cells.

[0005] In this connection, Korean Patent Registration No. 10-1022401 is known as a method for introducing a suicide gene into a mesenchymal stem cell to enhance targeting and treat cancer. However, KR 10-1022401 does not disclose a combination therapy adjuvant for improving an effect of an anti-cancer agent by manipulating the mesenchymal stem cell in a special environment and administering the mesenchymal stem cell in combination with another anti-cancer agent, and does not disclose a method for periodic administration.

[0006] Further, recently, a number of studies on combination therapies such as combination therapy of two or more kinds of anti-cancer agents have been conducted. In this regard, not only a combination therapy of a chemotherapeutic agent, but also a combination therapy of a chemotherapeutic agent in combination with different kinds of anti-cancer therapies, etc., has been recently reported. However, in the case of combination therapy, there are many cases in which combination administration of each drug shows a simple additive effect of the same degree of drug efficacy.. Further, unpredictable side effects have been reported, for example, an effect of the drugs is rather deteriorated by an interaction of the drugs, etc. Thus, studies on the combination administration of drugs are still continuing.

[0007] In connection with the combination administration in cancer, there is also a study on the combination therapy of chemotherapeutic agents and cell therapeutic agents, such as mesenchymal stem cells. However, in the combination therapy using the mesenchymal stem cells, researches aiming at administration of cells such as autologous stem cells for recovery of cells damaged after anti-cancer therapy by chemotherapeutic agents have been intensively conducted, and there are not many attempts to utilize the stem cells themselves as therapeutic agents for combination therapy. Chang, D.Y., Yoo, S.W., Hong, Y., Kim, S., Kim, S.J., Yoon, S.H., Cho, K.G., Paek, S.H., Lee, Y.D., Kim, S.S. and Suh-Kim, H., 2010. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. International journal of cancer, 127(8), pp.1975-1983, discloses the potential advantages of autograftable MSCs compared with other types of allogeneic stem cells for the treatment of recurrent glioblastomas through repetitive treatments. Nouri, F.S., Wang, X. and Hatefi, A., 2015. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. Journal of controlled release, 200, pp.179-187, discloses that yCD:UPRT/5-FC is the most effective enzyme/prodrug system among TK (TK₀₀₇ and TK_SR39 mutants), yeast cytosine deaminase:uracil phosphoribosyltransferase (yCD:UPRT) and nitroreductase (NTR). Jung, J.H., Kim, A.A., Chang, D.Y., Park, Y.R., Suh-Kim, H. and Kim, S.S., 2015. Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells. American journal of cancer research, 5(9), p.2686, discloses a method to assess bystander effects of therapeutic stem cells against 3-dimensionally grown glioma cells in real time.

[0008] Therefore, there is a need to develop a therapeutic agent and a treatment method capable of having high targeting so that cancer or tumor therapeutic agents are able to be accurately transferred to a cancer tissue, being non-toxic so as not to affect parts other than the tumor, and being repeatedly administered until cancer is eliminated because of no immunotoxicity. Further, there is a need and requirement for a novel therapeutic method, therapeutic agent, therapeutic adjuvant and combination therapy that are able to improve or enhance the efficacy of existing anti-cancer agents.

[Disclosure]

[Technical Problem]

[0009] The present inventors studied a novel cancer therapeutic agent that is capable of overcoming the limitations of the existing chemotherapy, found that cells prepared by introducing a cytosine deamine gene into a mesenchymal stem cell to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD), followed by freezing and thawing, could exhibit very excellent tumor suppressive effect and survival rate improvement effect as compared to simply cultivated MSC/CD cells, and maximize effects of combination therapy with existing anti-cancer agents, and completed the present disclosure.

[0010] An object of the present disclosure is to provide a method for preparing a cell therapeutic agent, a cell therapeutic agent for use in cancer treatment, a combined administration agent with the cell therapeutic agent and a chemotherapeutic agent.

[Technical Solution]

[0011] The embodiment of the present invention is reflected in independent claims 1 and 2. The preferred embodiments of the present invention are reflected in dependent claims 3 to 9. In order to achieve the foregoing objects, the present disclosure provides a method for preparing cell therapeutic agent, comprising: 1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD); 2) freezing the prepared MSC/CD to prepare frozen MSC/CD; and 3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent.

[0012] In addition, the present disclosure provides a cell therapeutic agent for use in cancer treatment.

[0013] Further, the present disclosure provides a cell therapeutic agent for use in cancer treatment with 5-fluorocytosine (5-FC).

[0014] In addition, the present disclosure provides a cell therapeutic agent for use in cancer treatment comprising: 1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD); 2) freezing the prepared MSC/CD to prepare frozen MSC/CD; 3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent; 4) administering the cell therapeutic agent to a subject in need of treatment; and 5) administering 5-fluorocytosine (5-FC) to a subject in need of treatment.

[Advantageous Effects]

[0015] According to the preparation method of the present disclosure, it is possible to provide the cell therapeutic agent, in spite of having no difference in the proliferative capacity compared with mesenchymal stem cells expressing cytosine deaminase, which are harvested and used immediately after culturing, exhibit a very excellent tumor suppressive effect through the treatment together with 5-FC, and induce a remarkable synergistic effect exceeding an effect from combination therapy with an existing anti-cancer agent, even in cases of a combination therapy with another anti-cancer agent. Therefore, the present disclosure may be utilized as a kit for cancer treatment comprising such cell therapeutic agent, and thus may be favorably used to maximize the effect of existing cancer treatments.

[Description of Drawings]

[0016] 

FIG. 1 is a schematic diagram of a mesenchymal stem cell line (MSC/CD) that stably expresses cytosine deaminase, an suicide effect thereof, and a bystander effect.

FIG. 2 shows treatment process of MSC or MSC/CD with 5-FC (A) and results of the suicide effect (B) derived therefrom.

FIG. 3 shows treatment of MSC or MSC/CD with 5-FC (A) and results of the bystander effect (B, C) derived therefrom.

FIG. 4 shows process of cell preparation and treatment of I cell, cell therapeutic agent (DMSO, noted as F cell (DSMO) in the figure), and cell therapeutic agent (CS10, noted as F cell (CS10) in the figure) (A) for comparing bystander effect on respective cells and bystander effects (B) on respective cells.

FIG. 5 shows a microscopic observation of a colony forming ability of the I cell and the cell therapeutic agent (noted as F cell in the figure) (A), and a graph for comparing quantitative analysis results using CFU-A (colony forming unit assay)(B).

Fig. 6 shows a process of treating the I-cell or the cell therapeutic agent (noted as F cell in the figure) with 5-FC in a brain tumor model (A), results of brain tumor changes following the treatment observed under a dissecting microscope obtained by observing brain tumor changes by the treatment (B), and tumor volume changes (C).

FIG. 7 shows a graph for tumor volume changes according to the I cell or the cell therapeutic agent treatment (noted as F cell in the figure) (A) in subcutaneous tumor models in which liver cancer cells are implanted subcutaneously, and representative tumor models showing an external size of the tumor (B).

FIG. 8 shows tumor volume changes according to the I cell or the cell therapeutic agent treatment (noted as F cell in the figure), in subcutaneous tumor models in which pancreatic cancer cells are implanted subcutaneously (A), in subcutaneous tumor models in which lung cancer cells are implanted subcutaneously (B), and in subcutaneous tumor models in which colon cancer cells are implanted subcutaneously (C).

FIG. 9 shows cell therapeutic agent + 5-FC + TMZ combination therapy (A), the bystander effects derived therefrom (B, C), confirmation on results of cell death through fluorescence images of U87MG expressing GFP (D), and isobologram results of IC₅₀ values (E).

FIG. 10 shows the cell therapeutic agent + 5-FC + anti-cancer agent combination therapy (A), isobologram results of IC₅₀ values of carmustine (B), and isobologram results of IC₅₀ values of irinotecan (C), respectively, in anti-cancer agent combination therapy.

FIG. 11 shows process of the cell therapeutic agent + 5-FC + temozolomide (TMZ) combination therapy (A), the results of brain tumor changes following the treatment observed under a dissecting microscope showing brain tumor changes (B), tumor volume changes (C), and synergistic effects in improvement of survival rates (D) by the combination therapy.

FIG. 12 shows the analysis process on effects of the I cell or the cell therapeutic agent + 5-FC + temozolomide (TMZ) combination therapy in the subcutaneous tumor models (A), tumor volume changes (B), and synergistic effects of the cell therapeutic agent + 5-FC + temozolomide (TMZ) in analysis of survival rates (C).

[Best Mode]

[0017] The present disclosure provides a method for preparing cell therapeutic agent, including: 1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD); 2) freezing the prepared MSC/CD to prepare frozen MSC/CD; and 3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent.

[0018] According to the method for preparing cell therapeutic agent of the present disclosure, it is possible to provide the cell therapeutic agent, in spite of having no difference in the proliferative capacity compared with mesenchymal stem cells expressing cytosine deaminase, which are harvested and used immediately after culturing I cells, exhibit a very excellent tumor suppressive effect when treated with 5-FC, and induce a remarkable synergistic effect exceeding an effect from combination therapy with an existing anti-cancer agent, even in cases of a combination therapy with another anti-cancer agent.

[0019] The "MSC/CD" used herein refers to a mesenchymal stem cell prepared to express cytosine deaminase (CD) in the mesenchymal stem cell. The mesenchymal stem cell into which the cytosine deaminase is introduced refers to a cell that moves to the vicinity of cancer cells with a tropism towards the cancer cells, and continuously expresses cytosine deaminase to induce suicide effect itself, and converts an non-toxic prodrug into an active anti-cancer agent to exhibit a bystander effect in which surrounding cancer cells are killed. The MSC/CD is advantageous in that since it undergo cell death, side effects that may be caused by undesired continuous effects may be reduced, and since it moves to the vicinity of cancer cells, infiltrative cancer cells may be killed, thereby acting as an effective anti-cancer agent. In particular, the "F cell", which is a cell prepared by freezing/thawing the MSC/CD, exhibits synergistic effect in which an anti-cancer effect is significantly increased when used in combination with the existing anti-cancer agent, thereby being utilized as an adjuvant enhancing the effect of the anti-cancer agent.

[0020] The term "mesenchymal stem cell (MSC)" of the present disclosure is a kind of stem cells that are able to be collected from bone marrow and umbilical cord blood, and is referred to a multipotent stromal cell that is capable of proliferation, and in particular, that is capable of being differentiated into various types of cells such as bone cells, cartilage cells, muscle cells, and fat cells, unlike hematopoietic stem cells. Therefore, the mesenchymal stem cell of the present disclosure may preferably be the multipotent mesenchymal stem cell.

[0021] Term "cytosine deaminase" of the present disclosure is a suicide gene, which functions to convert a prodrug harmless to the human body into a cytotoxic anticancer material, and specifically, a gene that converts 5-fluorocytosine (5-FC) which is a prodrug of 5-fluorouracil (5-FU), into 5-FU.

[0022] The suicide gene may be introduced into the mesenchymal stem cell according to methods for intracellular introduction of genes known in the art, such as a method of using a non-viral vector or a virus vector including the same, or a physical method. Examples of such physical methods for gene transfer may include electroporation, hydroporation, injection, etc. Examples of gene transfer using non-viral vectors may include methods of using cationic lipids, lipid polymers, or nanoparticles. The viral vector may include, without limitation, a replicable viral vector, a non-replicable viral vector, such as an adenoviral vector, an adeno-associated viral vector, a retroviral vector, herpes simplex virus, a hybrid adenoviral system, pox virus, a lentivirus vector, and Epstein Barr virus.

[0023] For example, in an exemplary embodiment of the present disclosure, the suicide gene may be introduced into the retrovirus vector to construct an expression vector, the vector may be transfected into packaging cells, the transfected packaging cells may be cultured and filtered to obtain a retrovirus solution, and this retrovirus solution may be used to transfect the mesenchymal stem cell, thereby inserting the suicide gene into the mesenchymal stem cell. Next, the mesenchymal stem cell that continuously expresses the suicide gene may be obtained using a selection marker included in the retrovirus vector.

[0024] In addition, since mesenchymal stem cell is known to have low immunorejection even during allotransplantation, it is possible to use either cells isolated from others or cells collected from patients with cancer themselves, and to further minimize immunorejection among individuals through separation from bone marrow having similar HLA (human leukocyte antigen) types using a database of blood banks.

[0025] The MSC/CD of the present disclosure may be obtained by introducing a suicide gene into the isolated stem cell at first, followed by screening, proliferation and differentiation under an appropriate condition in a test tube, or may be obtained by sufficiently proliferating the stem cell, introducing a suicide gene into the stem cell, followed by differentiation into the mesenchymal stem cell. The MSC/CD is injected into a subject in need of treatment by the presence of the suicide gene, and kills themselves after, for example, 2 to 30 days, preferably 5 to 15 days, more preferably 5 to 10 days, but is not limited thereto, from the injection, thereby reducing side effects that may be induced by continuous action.

[0026] Term "F cell (frozen cell)" of the present disclosure refers to a cell that is not undergone an additional culturing step, free of culturing the cell therapeutic agent, after freezing and thawing the MSC/CD, which is the mesenchymal stem cell into which the cytosine deaminase (CD) is introduced, and is defined as a cell being thawed and suspended, or suspended and washed with a purpose of administration of cells to the subject to be treated. More specifically, the F cell refers to a cell obtained by introducing cytosine deaminase (CD) into the mesenchymal stem cell to prepare the MSC/CD, culturing, freezing the cell in a freezing medium, thawing the cell at room temperature immediately before use, followed by suspension, for example, in a Plasma Solution A, or the like, containing human serum albumin, which is not limited thereto, and centrifugation. As a cell differentiated from the cell therapeutic agent of the present disclosure, an immediately harvested cell (I cell)" may be exemplified, which is obtained by performing the same freezing and thawing step on the MSC/CD, but maximizing the concentration and activity through the subsequent culturing process, and is used by directly harvesting the cell in the culture.

[0027] The cell therapeutic agent, compared to the I cell, of the present disclosure is characterized in that the anti-cancer effect is increased without culturing step, which is performed generally to maximize activation and without increasing a colony forming ability. In addition, the cell therapeutic agent of the present disclosure may have an advantage of being immediately administered to a patient in need of treatment together with the improvement of the anti-cancer effect.

[0028] In the present disclosure, the cells in a cryopreserved state or frozen state may be stored by using any means known in the art for maintaining the cells to be in frozen state, such as a freezing preservation liquid, a freezing medium, etc. For example, the means may include media including freezing protectants such as dimethylsulfoxide (DMSO), dextran, human serum, human serum albumin, bovine serum, bovine serum albumin, poly-l-lysine, polyvinylpyrrolidone, hydroxy-ethyl-starch, ethylene glycol, polyethylene glycol, glycerol, and percoll (for example, cryostor CS2, cryostor CS10 commercially available from BioLife Solutions Inc.), and specifically, cryostor CS2, cryostor CS10, and 2 to 10% DMSO medium, and more specifically, 2, 5, and 10% DMSO media, etc.

[0029] The cell therapeutic agent of the present disclosure exhibits in vitro colony forming ability similar to that of the I cell, and also effectively exhibits the bystander effect of the MSC/CD. Further, the cell therapeutic agent exhibits an inhibitory effect in vivo on a variety of tumors including brain tumors and subcutaneous tumors twice or higher as compared to the I cell or the control group, and exhibits a highly elevated anti-cancer effect in the combination therapy with temozolomide (TMZ) which is the existing anti-cancer agent. In other words, even though the cell therapeutic agent has no difference in the colony forming ability as compared to the I cell, the cell therapeutic agent exhibits a remarkable anti-cancer effect that are not able to be expected in vitro and an effect as an anti-cancer agent adjuvant, as compared to other I cells, due to the intrinsic activity of the cell therapeutic agent given according to the preparation method.

[0030] That is, the F cells of the present disclosure may be differentiated from I cells that are conventionally used, by preparation methods in which cell culturing is not further performed after freezing.

[0031] Therefore, the present disclosure provides the method for preparing cell therapeutic agent characterized in that the cell therapeutic agent is not subjected to cell culturing after freezing.

[0032] The cell therapeutic agent of the present disclosure is usable for cancer treatment. The cell therapeutic agent may be used to treat, without limitation, all carcinomas capable of being extracted as cancer and carcinoma, and may be administered to a subject in need of treatment before, simultaneously with, and after chemotherapy using administration of anti-cancer agent.

[0033] The cancer may be, for example, at least one selected from the group consisting of squamous cell cancer (for example, squamous cell cancer of epithelium), small cell lung cancer, non-small cell lung cancer, lung cancer, peritoneal cancer, colorectal cancer, biliary tumor, nasopharyngeal cancer, laryngeal cancer, bronchial cancer, oral cancer, osteosarcoma, gallbladder cancer, kidney cancer, leukemia, bladder cancer, melanoma, brain cancer, glioma, brain tumor, skin cancer, pancreatic cancer, breast cancer, liver cancer, bone cancer, esophageal cancer, colon cancer, gastric cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck cancer, and rectal cancer, and more preferably, brain tumor, pancreatic cancer, liver cancer, lung cancer, colon cancer, and skin cancer.

[0034] Further, the cell therapeutic agent of the present disclosure may also be an adjuvant for anti-cancer. The adjuvant for anti-cancer refers to an adjuvant that is capable of inducing faster action of a primary therapy and strongly forming an anti-cancer action thereof by combination therapy with the primary therapy, for example, cancer treatment by chemical therapy or surgical operation. The adjuvant for anti-cancer may be used to enhance the effect of anti-cancer agent, which is a main therapeutic agent primarily used in chemotherapy using the anti-cancer agent, and may be used to maximize cancer treatment effect by treating residual cancer cells after surgery.

[0035] The cell therapeutic agent may be present in a form of a composition for use in cancer therapy or for use in the adjuvant for anti-cancer, and such a composition may include pharmaceutically acceptable excipients, carriers and diluents. A particularly preferred injection form is preferably formulated into an injection form suitable for injection into a tissue or organ.

[0036] Accordingly, the present disclosure provides an adjuvant for anti-cancer including the cell therapeutic agent.

[0037] The cell therapeutic agent may be injected into the patient's body according to the physician's prescription or by a method well known in the art, and a single dose will be determined in consideration of various related factors such as a disease to be treated, the severity of the disease, the route of administration, the body weight, age, and sex of the patient, etc.

[0038] Further, the present disclosure provides a kit for cancer treatment including the cell therapeutic agent, and 5-fluorocytosine (5-FC).

[0039] The kit for cancer treatment is prepared for the purpose of the combination therapy of cell therapeutic agent and 5-fluorocytosine (5-FC), and means a kit prepared so that the cell therapeutic agent is able to be injected before, simultaneously with, and after administration of 5-fluorocytosine (5-FC) which is a prodrug, to a subject in need of treatment.

[0040] The kit for cancer treatment may comprise a first compartment and a second compartment, wherein the first compartment may comprise the cell therapeutic agent for cancer treatment or the cell therapeutic agent acting as an adjuvant for anti-cancer, and the second compartment may include 5-fluorocytosine (5-FC). The kit may be contained in one container or in several different small containers with each divided dosage in order to improve convenience and portability. Therefore, several containers may exist in each container according to an arrangement method. The kit of the present disclosure may include, if necessary, equipment necessary for use, instructions including descriptions of administration methods for each component, etc.

[0041] In addition, a kit for cancer treatment of the present disclosure may further include an anti-cancer agent. The anti-cancer agent may include, but is not limited to, anti-cancer agents known in the art, and preferably may be at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, elotinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, sorafenib, bevacizumab, cetuximab, viscum album, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tiuxetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazine, alprostadil, holmium nitrate chitosan, gemcitabine, doxifluridine, pemetrexed, tegafur, capecitabine, gimeracil, oteracil, azacytidine, cytarabine, fludarabine, enocitabine, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, belotecan, topotecan, vinorelbine, etoposide, vincristine, vinblastine, tenifocide, idarubicin, epirubicin, mitoxantrone, mitomycin, bleomycin, daunorubicin, dactinomycin, pirarubicin, aclarubicin, pepromycin, temozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altretamine, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, taxotere, gleevec, taxol, herceptin, tarceva, avastin, zoladex, adriamycin, irinotecan, 10058-F4, cisplatin, cyclophosphamid, nitrosourea-based anti-cancer agent, methotrexate, and doxorubicin. The nitrosourea includes carmustine, lomustine, and the like. The anti-cancer agent may be included in the third compartment of the kit for cancer treatment.

[0042] In addition, the present disclosure provides a method for preventing or treating cancer including: 1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD); 2) freezing the prepared MSC/CD to prepare frozen MSC/CD; 3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent; 4) administering the cell therapeutic agent to a subject in need of treatment; and 5) administering 5-fluorocytosine (5-FC) to a subject in need of treatment.

[0043] The subject is preferably a mammal, including a human, and may include all of a patient in need of cancer treatment, a patient undergoing cancer treatment, a patient experienced with cancer treatment, and a patient who need to be treated for cancer, and may also include a patient who underwent surgery to extract the cancer for cancer treatment.

[0044] Further, the present disclosure provides the method for preventing or treating cancer, further including: 6) administering an anti-cancer agent to a subject in need of treatment.

[0045] Further, the present disclosure provides a cell therapeutic agent for use of preventing or treating cancer including: 4) administering an anti-cancer agent to a subject in need of treatment before, simultaneously with administration of the cell therapeutic agent of step 4).

[0046] That is, the present disclosure provides the cell therapeutic agent for use of preventing or treating cancer including both of simultaneous administration of the cell therapeutic agent and the anti-cancer agent to a subject in need of treatment, and sequential administration, such as administration of the anti-cancer agent after administration of the cell therapeutic agent, and administration of the cell therapeutic agent after administration of the anti-cancer agent to a subject in need of treatment.

[0047] The anti-cancer agent may include, but is not limited to, anti-cancer agents known in the art, and preferably may be at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, elotinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, sorafenib, bevacizumab, cetuximab, viscum album, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tiuxetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazine, alprostadil, holmium nitrate chitosan, gemcitabine, doxifluridine, pemetrexed, tegafur, capecitabine, gimeracil, oteracil, azacytidine, cytarabine, fludarabine, enocitabine, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, belotecan, topotecan, vinorelbine, etoposide, vincristine, vinblastine, tenifocide, idarubicin, epirubicin, mitoxantrone, mitomycin, bleomycin, daunorubicin, dactinomycin, pirarubicin, aclarubicin, pepromycin, temozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altretamine, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, taxotere, gleevec, taxol, herceptin, tarceva, avastin, zoladex, adriamycin, irinotecan, 10058-F4, cisplatin, cyclophosphamid, nitrosourea-based anti-cancer agent, methotrexate, and doxorubicin. The nitrosourea includes carmustine (BCNU), lomustine (CCNU), etc. The anti-cancer agent may be appropriately and selectively prescribed according to a prescription dose of the anticancer agent which is widely known in the art, but may be prescribed at a dose smaller than an average prescription dose in consideration of the synergistic effect with the cell therapeutic agent of the present disclosure.

[0048] The cell therapeutic agent of the present disclosure and 5-fluorocytosine may be administered simultaneously or sequentially with time differences, which may be selected depending on appropriate time and period for conversion of 5-fluorocytosine to 5-fluorouracil by the cell therapeutic agent.

[0049] Therefore, the present disclosure provides the method for preventing or treating cancer characterized in that the cell therapeutic agent and the 5-fluorocytosine are administered simultaneously or sequentially.

[0050] Further, the anti-cancer agent used in combination with the 5-fluorocytosine of the present disclosure may be administered simultaneously or sequentially with time differences, and may be selected according to appropriate time and period.

[0051] Therefore, the present disclosure provides the cell therapeutic agent for use of preventing or treating cancer characterized in that the 5-fluorocytosine and the anti-cancer agent are administered simultaneously or sequentially.

[0052] The sequential administration in the present disclosure means that multiple components to be administered are administered to a subject with time differences, and the order of each of active components may be appropriately adjusted.

[0053] The cell therapeutic agent may be delivered in a pharmaceutically effective amount to a tumor site of the subject, and the delivery is preferably performed by an injection form, but is not limited thereto. In particular, it is more preferable that the injection is administered for mammals, preferably a human patient.

[0054] The cell therapeutic agent are the MSC/CD cells that are immediately used by freezing, thawing, or thawing and washing, and have an cytotoxic effect, which may be killed in a subject body for a predetermined period of time by a suicide effect, preferably 5 to 15 days after injection. Thus, the cell therapeutic agent may be repeatedly administered for continuous treatment. Further, the 5-FC, the anti-cancer agent may be repeatedly administered depending on the therapeutic purpose and the condition of the patient. The cycle of the repeated administration of the cell therapeutic agent, 5-FC, and the anti-cancer agent may be appropriately adjusted according to the therapeutic condition of the patient, and the cycle may be preferably every 10 to 30 days. For example, in consideration of the cell death of the MSC/CD, the repeated administration is preferable after at least 10 days, and the repeated administration every 30 days is also preferable considering that the cells are injected with a syringe.

[0055] Therefore, the present disclosure provides the method for preventing or treating cancer characterized in that the administration of the cell therapeutic agent is repeated every 10 to 30 days.

[0056] Depending on the repetition of the cell therapeutic agent administration cycle, the 5-fluorocytosine may also be repeatedly administered periodically, and optionally, the anti-cancer agent for combined administration may also be repeatedly administered periodically.

[0057] In the method for preventing or treating cancer of the present disclosure, cell therapeutic agent may be used to treat, without limitation, all carcinomas capable of being extracted as cancer and carcinoma, and may be administered to a subject in need of treatment before, simultaneously with, and after chemotherapy using administration of anti-cancer agent. The cancer may be, for example, at least one selected from the group consisting of squamous cell cancer (for example, squamous cell cancer of epithelium), small cell lung cancer, non-small cell lung cancer, lung cancer, peritoneal cancer, colorectal cancer, biliary tumor, nasopharyngeal cancer, laryngeal cancer, bronchial cancer, oral cancer, osteosarcoma, gallbladder cancer, kidney cancer, leukemia, bladder cancer, melanoma, brain cancer, glioma, brain tumor, skin cancer, pancreatic cancer, breast cancer, liver cancer, bone cancer, esophageal cancer, colon cancer, gastric cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck cancer, and rectal cancer, and more preferably, brain tumor, pancreatic cancer, liver cancer, lung cancer, colon cancer, and skin cancer.

[0058] Hereinafter, preferred Preparation Examples and Examples of the present disclosure will be described to assist in understanding the present disclosure. However, the following Preparation Examples and Examples are provided only to more easily understand the present disclosure, and therefore, the present disclosure is not limited thereto.

Preparation Example 1: Preparation of mesenchymal stem cell expressing cytosine deaminase (CD)

1.1 Isolation and culture of mesenchymal stem cell

[0059] 4 ml of human bone marrow donated after the IRB examination of Ajou University Medical Center was overlaid on 4 ml of HISTOPAQUE 1077 (Sigma-Aldrich) in a sterilized 15 ml test tube, and centrifuged at 400 x g for 30 minutes at room temperature using a centrifuge. After centrifugation, 0.5 ml of the intermediate buffy coat was carefully collected using a Pasteur pipette, and transferred to a test tube containing 10 ml of sterilized phosphate buffer solution (pH 7.4) After centrifugation at 250 x g for 10 minutes, the supernatant was discarded, and 10 ml of phosphate buffer solution was added and gently suspended, followed by centrifugation at 250 x g for 10 minutes. This procedure was repeated twice, and the final precipitate was added to a DMEM medium (Gibco) supplemented with 10% FBS (Hyclone) and dispensed in a 100 mm animal cell culture dish to obtain 1 x 10⁹ cells. The culture container was placed in an incubator and cultured at 37°C for 4 hours while supplying 5% carbon dioxide and 95% air. Subsequently, in order to remove cells that did not stick to the bottom of the culture container, the supernatant was removed. A fresh medium was added thereto, and cultured in an incubator.

[0060] The isolated mesenchymal stem cells were maintained in a CO₂ incubator at 37°C, and cultured in a mesenchymal stem cell culture medium [(10% FBS (Gibco) + 10 ng/ml bFGF (Sigma-Aldrich) + 1% penicillin/streptomycin (Gibco) + 89% DMEM (Gibco)]. The cells were cultured while replacing the medium every two days. When the cells reached about 80% in the culture container, the cells were isolated using 0.25% trypsin/0.1 mM EDTA (Gibco), diluted so as to satisfy about 800 to 1,1000 cells/cm², or 1 : 10 to 1 : 20 with the medium, and subcultured in a new culture container. Some of the cells were stored frozen by a freezing medium supplemented with 2-10% DMSO (Sigma-Aldrich, 2, 5, 10%).

1.2 Preparation of retrovirus including cytosine deaminase (CD)

[0061] A retrovirus expressing cytosine deaminase (CD), a suicide gene, was constructed. Detailed description thereof is as follows:
DNA was isolated from E. coli K-12 MG1655 (Korea Research Institute of Bioscience and Biotechnology), and then PCR was performed under conditions of 5 minutes at 94°C, 30 seconds at 94°C, 40 seconds at 60°C, 1 minute at 72°C, 27 cycles; 7 minutes at 72°C using primers CD-F(5'-GAA TTC AGG CTA GCA ATG TCT CGA ATA ACG CTT TAC AAA C-3') and CD-R (5'-GGATTC TCT AGC TGG CAG ACA GCC GC-3'). The PCR product was using a pGEM-T Easy vector cloning kit (Promega), and then a PGEM-CD vector containing the CD gene was constructed through blue-white colony screening using X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, Sigma-Aldrich) and IPTG (Isopropyl β-D-1-thiogalactopyranoside, Sigma-Aldrich). It was confirmed that the base sequence of the obtained CD gene was identical to that of gi: 298594 of GeneBank through sequence analysis. The prepared pGEM-CD plasmid and pcDNA3.1 (Clontech) were digested with EcoRI and NotI restriction enzymes, respectively, and the CD gene isolated from the plasmid pGEM-CD and the cut plasmid pcDNA3.1 were ligated with T4 DNA ligase. Then, the obtained product was used to transform E. coli DH5α, a competent cell, and cultured on an LB plate containing 50 µg/ml of ampicillin and selected to obtain a plasmid pcDNA3.1-CD. This plasmid was digested with BamH I restriction enzyme and introduced into a retroviral vector capable of producing retrovirus. The obtained plasmid was isolated by a CsCl-ultra highspeed centrifuge, and transfected into FLYRD18 cell, which is a retrovirus packaging cell line, by calcium phosphate precipitation (Jordan, Nucleic Acid Research, 24, 596-601 (1996)). Then, the cells were cultured at 37°C in an incubator while supplying 5% carbon dioxide and 95% air. After 48 hours, only the culture solution was obtained and filtered through a 0.45 µm filter membrane to obtain a retrovirus solution. The retrovirus solution was dispensed and used while storing at -70°C.

1.3 Preparation of mesenchymal stem cell into which CD gene is introduced

[0062] The CD gene was introduced into the mesenchymal stem cell isolated and cultured in the description of 1.1, using the CD-containing retrovirus prepared in the description of 1.2. More specifically, the mesenchymal stem cell was cultured to reach about 70% in a 100 mm culture dish. Then, 3 ml of the retrovirus solution, 3 ml of the fresh mesenchymal stem cell culture medium, and 4 µg/ml of polybrene (Sigma-Aldrich) were added and cultured for 8 hours. Then, the virus solution was removed, 10 ml of mesenchymal stem cell culture medium was added and cultured for 16 hours, and then infected again with retrovirus. After this procedure was performed 1 to 3 times, the mesenchymal stem cell was finally taken off with trypsin and subcultured by 1:20 dilution with the medium. In the subculture, puromycin (Sigma-Aldrich) was added to the medium to a concentration of 2 µg/ml. The cells were screened for 2 weeks so that only cells infected with retrovirus could survive. Finally, the mesenchymal stem cell line (hereinafter, referred to as MSC/CD) continuously expressing CD, which is a suicide gene, was constructed.

Example 1. Suicide effect and bystander effect of MSC/CD

1.1 Confirmation of suicide effect

[0063] The cytosine deaminase (CD) is a suicide gene. The MSC/CD, which is a mesenchymal stem cell expressing the cytosine deaminase (CD), may convert 5-fluorocytosine (5-FC) which is a prodrug into 5-fluorouracil (5-FU) and may have a suicide effect (the cells kill themselves) and a bystander effect (peripheral cells are killed) as shown in FIG. 1. Therefore, the suicide effect and the bystander effect of the MSC/CD prepared in the description of 1.3 were confirmed. First, 10,000 MSC/CD or mesenchymal stem cells (MSCs) were cultured in a 12-well plate. From the next day, the cells were treated with the prodrug 5-FC at a concentration of 0 to 1,000 µM, and replaced with a new medium containing the drug once every two days. The medium was changed to a cell culture medium containing 0.5 mg/ml of MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) capable of measuring living cells on the 6^th day after treatment with 5-FC, and reacted for 2 hours at 37°C. Then, the MTT solution was removed. 500 µl of DMSO was added to each well to perform a color reaction. Then, the lysates were transferred to a 96-well plate and absorbance was measured at 540 nm using an ELISA reader (E-max, Molecular device). A schematic diagram of the experimental method and the results thereof are shown in FIG. 2.

[0064] As shown in FIG. 2, it was confirmed that the MSC/CD had a suicidal effect in which the living cells were reduced as the concentration of the prodrug 5-FC was increased, and IC₅₀ inducing 50% cell death was 60.4 µM. In the case of mesenchymal stem cell, which is the control group, it was confirmed that even if the concentration of 5-FC was increased, the cells did not kill themselves, and thus, the cytototoxic effect was not observed.

1.2 Bystander effect

[0065] 10,000 GFP-expressing U87MG (Korean Cell Line Bank KCLBNo.30014) glioma cells and 10,000 MSC/CD or mesenchymal stem cells (MSCs) were cultured on a 12-well plate. From the next day, the cells were treated with the prodrug 5-FC at a concentration of 0 to 1,000 µM, and replaced with a new medium containing the drug once every two days, and after 6 days, the cells were obtained. Such an experimental method is briefly shown in FIG. 3A.

[0066] Then, fluorescence images of U87MG expressing GFP remaining in the whole well were taken using an dissecting fluorescence microscope (Olympus). After the fluorescence images were taken, 200 µl of 1X passive lysis buffer (Promega) was added, and the cell lysate was placed on ice for 10 minutes and transferred to an E-tube and centrifuged at 12,000 rpm for 5 minutes, and the supernatant was transferred to a new container. 100 µl of the supernatant was transferred to a black 96-well plate, and the degree of fluorescence was measured under conditions of excitation 488 nm and emission 530 nm using a fluorimeter (GEMINI EM, molecular device). The results are shown in FIGS. 3B and 3C.

[0067] As shown in FIGS. 3B and 3C, U87MG cultured with MSC/CD showed a decrease in the number of cells expressing fluorescence and a remarkable decrease in fluorescence intensity as the concentration of 5-FC was increased, but U87MG cultured with the mesenchymal stem cells in which the CD was not expressed did not show a significant difference in the number of cells expressing fluorescence and fluorescence intensity according to the concentration of 5-FC. Herein, IC₅₀ inducing 50% cell death was 50.48 µM. The results indicated that the MSC/CD, which is the mesenchymal stem cell into which the CD was introduced, showed not only the suicide effect but also the bystander effect in which the peripheral cells were killed together.

Preparation Example 2. Preparation of "I cell" and the cell therapeutic agent "F cell"

[0068] In the case of a cell therapy agent, the effect may vary depending on the change in the cell state under various conditions. Therefore, in order to confirm whether the cell ability was changed according to the state of MSC/CD, cells in a thawed state immediately after freezing (hereinafter, referred to as F cells (frozen cells)), and cells in a harvested state immediately from the cells during the culturing (hereinafter, referred to as I cells (immediately harvested cells)) were prepared.

[0069] In order to prepare the cell therapeutic agent and the I cells, respectively, the MSC/CD was cultured, and then 2 × 10⁶ cells were dispensed in 1 ml of freezing medium containing 2 to 10% (2, 5, 10%) DMSO or 2X10⁶ cells were dispensed in 1 ml of Cryostor CS10 (BioLife Solutions). The cells were frozen and stored in a liquid nitrogen container. First, in order to obtain "I cells" of MSC/CD, cells of passage 5 were dissolved at 37°C, and placed in 9 ml of culture medium. Then, the cells were centrifuged at 500 g for 5 minutes to remove the supernatant, and the precipitated cells were suspended in the culture solution, and dispensed in a 150 mm culture container. The next day, 1.5 X 10⁵ cells were transferred to the 150 mm culture container, and replaced with new medium once every two days. After 6 days, the cells were collected to prepare "I cells" corresponding to passage 6.

[0070] In order to obtain the cell therapeutic agent "F cells", the MSC/CD frozen and stored in the passage 6 at - 130°C or below was dissolved at 37°C and suspended in a Plasma Solution A (CJ HealthCare Corp.) containing 9 ml of human serum albumin, followed by centrifugation at 500 xg for 5 minutes, or suspended in physiological saline containing a final 7.5% dextran-40 (Daihan Pharm Co., Ltd.) and 5% human serum albumin (Green Cross Corp.), followed by centrifugation at 800 xg for 10 minutes. Then, the supernatant was removed, and the precipitated cells were suspended in the culture medium and used. In other words, the cell therapeutic agent are cells that were not subjected to the culturing step after freezing and thawing. The I cells and the cell therapeutic agent were washed twice, respectively, before transplantation into the brain.

Example 1. Bystander effect and colony formation of F cells

1.1 Bystander effect of the cell therapeutic agent

[0071] Experiments were performed to determine whether the cell therapeutic agent could normally exhibit the bystander effect of MSC/CD and whether the bystander effect appeared effectively regardless of the preparation method such as the type of medium. 10,000 I cells prepared by the method of Preparation Example 2, cell therapeutic agent of 10,000 F cells prepared with 10% DMSO freezing medium (DMSO), and cell therapeutic agent of 10,000 F cells prepared with Cryostor CS10 (CS10) were washed with a Plasma Solution A, and were co-cultured in 12-well plates together with glioma U87/GFP cells in which GFP gene was transduced into U87MG (KCLB No.30014) donated from Korean Cell Line Bank so as to express fluorescence. From the next day, the cells were treated with the prodrug 5-FC at a concentration of 0 to 1,000 µM, and replaced with a new medium containing the drug once every two days, and after 6 days, the cells were obtained. 200 µl of 1X passive lysis buffer (Promega) was added, and the cells were placed on ice for 10 minutes. The cell lysate was transferred to an E-tube and centrifuged at 12,000 rpm for 5 minutes, and the supernatant was transferred to a new container. 100 µl of the supernatant was transferred to a black 96-well plate in which light is blocked, and the degree of fluorescence was measured under conditions of excitation 488 nm and emission 530 nm using a fluorimeter (GEMINI EM, molecular device). A schematic diagram of the experimental method and the bystander effect are shown in FIG. 4.

[0072] As shown in FIG. 4, the IC₅₀ values indicating concentration at which 50% of apoptosis is caused, was 60.4 µM for I cells, 56.2 µM for cell therapeutic agent prepared with 10% DMSO freezing medium (DMSO), and 55.4 µM for cell therapeutic agent prepared with Cryostor CS10 (CS10). These results indicated that the cell therapeutic agent was an agent that could effectively exhibit the bystander effect as compared to the I cell, and thus it was confirmed that the cell therapeutic agent exhibited the bystander effect more excellently as compared to the I cell regardless of the preparation method using the DMSO medium or the CS10 medium.

[0073] Therefore, hereinafter, the cell therapeutic agent prepared with the 10% DMSO freezing medium were used among the cell therapeutic agent prepared in Preparation Example 2.

1.2. Colony forming effect of cell therapeutic agent

[0074] A colony forming unit assay was performed to confirm whether the cell therapeutic agent prepared by freezing and thawing as in Preparation Example 2 exhibited a difference in proliferative capacity as compared to the I cells. The I cells prepared as in Preparation Example 2 and corresponding the same passage and the cell therapeutic agent prepared with 10% DMSO freezing medium were counted with Countess (Invitrogen), and then 100 cells were placed in a 100 mm culture container, respectively, and cultured while replacing the medium with a new medium once every two days. After 2 weeks, the cells were fixed with 10% formalin for 10 minutes, washed with phosphate buffer solution (Gibco), stained with a crystal violet solution (Sigma-Aldrich) for 10 minutes, and washed three times with water to obtain images by Versa doc (BioRad). The number of colonies formed by growing one cell for 2 weeks was visually counted, and showed in FIG. 5.

[0075] As shown in FIG. 5, it was confirmed that the I and cell therapeutic agent had no difference in the colony forming ability. These results indicated that the increased bystander effect of the cell therapeutic agent as compared to that of the I cells was not caused by an increase in the number of cells such as an increase in colony formation, and that the cell therapeutic agent itself exhibited more excellent bystander effect as compared to that of the I cells.

Example 2. Anti-cancer effect of cell therapeutic agent

2.1. Anti-cancer effect of cell therapeutic agent on brain tumor

[0076] In order to confirm the anti-cancer effect of the cell therapeutic agent on brain tumor, an orthotopic glioma model was constructed. First, 7-week-old immunodeficient nude mice (central experimental animals) were anesthetized and their mouths and ears were fixed in a sterotaxic frame. The head to be incised was sterilized with 70% ethanol, and the crown of head was vertically incised to about 0.5 cm. 3 x 10⁵/3µl of U87MG glioma cells expressing LacZ were transplanted at a rate of 0.3 µl/min at the brain coordinates of AP = +0.5 mm, ML = -1.8 mm, and DV = -3 mm, thereby constructing a brain tumor orthotopic glioma model. On the 3^rd day after transplantation of U87MG glioma cells expressing LacZ, the cell therapeutic agent prepared in Preparation Example 2 were suspended in a Plasma Solution A, followed by centrifugation at 500 x g for 5 minutes. The supernatant was discarded, and the washing procedure was repeated once or twice. Then, the cell suspension was prepared to have a concentration of 3 x 10⁵/6 µl. The cell suspension was transplanted at a rate of 0.3 µl/min at the brain coordinates of AP = +0.5 mm, ML = -1.8 mm, and DV = - 3 mm. From the next day after the cell transplantation, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. To compare the anti-cancer effect of the cell therapeutic agent, the I cells prepared in Preparation Example 2 were transplanted in the same manner, and 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week from the next day after the cell transplantation.

[0077] On the 28^th day after glioma cell transplantation, the animals were anesthetized, and perfused with physiological saline by inserting an injection needle into the left ventricle of the animals, and then, perfused with 10% formalin solution. The brain was extracted and fixed on a mouse brain matrix (Stoelting). Then, the brain was cut horizontally at intervals of 1 mm, and put in the same fixing fluid for 30 minutes, thereby fixing the brain slice. The brain slice was washed three times with phosphate buffered saline, immersed in phosphate buffered saline containing 20 mg/ml of X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, Koma Biotech), 5 mM potassium ferrocyanide/ ferricyanide (Sigma-Aldrich), 2 mM MgCl₂, and 0.02% NP40, and reacted at 37°C for 16 hours. An image of the brain tumor was obtained through an anatomic microscope. A size of the tumor was calculated using the image j (NIH) program and the following Equation, and the results are shown in FIG. 6.

[0078] As shown in FIG. 6, in the cell therapeutic agent transplantation group, the volume of the brain tumor was remarkably decreased, and more excellent effect was exhibited as compared to the I cell (B). The computed mean size of the tumor was 91.3 mm³ in the vehicle control group, 1.5 mm³ in the I cell transplantation comparison group, but 0.6 mm³ in the cell therapeutic agent transplantation animal group. That is, according to the in vivo results, it was confirmed that the cell therapeutic agent had a tumor-reducing effect twice more than that of the I cell among the MSC/CD, and the cell therapeutic agent could be a more effective anti-cancer agent.

2.2. Anti-cancer effect of cell therapeutic agent on liver cancer

[0079] 1 x 10⁵ Huh7 liver cancer cells (KCLB No. 60104) were suspended in 100 µl of a phosphate buffer solution containing 20% Matrigel (BD), and transplanted subcutaneously in 7-week-old immunodeficient nude mice (Balb/c nude). After 14 days from transplantation, when the tumor size reached 10 to 100 mm³, the I cells and the cell therapeutic agent prepared in Preparation Example 2 were injected. More specifically, the I cells and cell therapeutic agent prepared in Preparation Example 2 were suspended in the phosphate buffer solution, followed by centrifugation at 500 x g for 5 minutes. This procedure was repeated twice, and then the I cells or the cell therapeutic agent were prepared to have concentration of 1 x 10⁶/100 µl in the phosphate buffer solution and injected directly into the tumor using a syringe. From the next day after the I cell and cell therapeutic agent injection, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. The size of the tumor was measured once or twice weekly using a digital caliper, and the tumor volume was calculated using the following Equation, and the results are shown in FIG. 7.

[For measurement of tumor volume, see Cancer Chemother. Pharmacol. (1989) 24: 148-154]

[0080] As shown in A of FIG. 7, the tumor volume was more effectively decreased in the experimental group treated with the cell therapeutic agent, confirming that the cell therapeutic agent had more excellent anti-cancer effect than the I cell. As shown in B of FIG. 7, the increased anti-cancer effect was visually confirmed in the subcutaneous tumor model transplanted with the liver cancer cells, and thus, it was confirmed that the therapeutic effect of cell therapeutic agent was excellent (*, p < 0.05 upon comparison with the PBS group).

2.3. Anti-cancer effect of cell therapeutic agent on pancreatic cancer

[0081] BxPC3 pancreatic cancer cells (ATCC No. CRL-1687™) had a rapid growth rate and severe ulceration, and thus, 1 x 10⁶ BxPC3 pancreatic cancer cells, the I cells, and the cell therapeutic agent were injected simultaneously. More specifically, the I cells and cell therapeutic agent prepared in Preparation Example 2 were suspended in the phosphate buffer solution, followed by centrifugation at 500 x g for 5 minutes. This procedure was repeated twice, and then the I cells or the cell therapeutic agent were prepared to have concentration of 1 x 10⁶/100 µl in the phosphate buffer solution. 1 x 10⁶ I cells or cell therapeutic agent were suspended in 100 µl of a phosphate buffer solution containing 20% Matrigel (BD), and simultaneously transplanted subcutaneously in 7-week-old immunodeficient nude mice (Balb/c nude). From the next day after the cell injection, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week.

[0082] The tumor volume was measured in the same manner as in Example 2.2, and the measured tumor volume change was shown in FIG. 8A.

[0083] As shown in A of FIG. 8, the tumor volume was more effectively decreased in the experimental group treated with the cell therapeutic agent, confirming that the cell therapeutic agent had more excellent anti-cancer effect than the I cell, and had excellent therapeutic effect in the pancreatic cancer subcutaneous tumor model (*, p < 0.05 upon comparison with the PBS group).

2.4. Anti-cancer effect of cell therapeutic agent on lung cancer

[0084] 5 X 10⁶ A549 lung cancer cells (ATCC No.CCL-185™) were suspended in 100 µl of a phosphate buffer solution containing 20% Matrigel (BD), and transplanted subcutaneously in 7-week-old immunodeficient nude mice (Balb/c nude). After 8 days from transplantation, when the tumor size reached 20 to 50 mm³, the I cells and the cell therapeutic agent prepared in Preparation Example 2 were injected. More specifically, the I cells and cell therapeutic agent prepared in Preparation Example 2 were suspended in the phosphate buffer solution, followed by centrifugation at 500 x g for 5 minutes.

[0085] This procedure was repeated twice, and then the I cells or the cell therapeutic agent were prepared to have concentration of 1 x 10⁶/100 µl in the phosphate buffer solution and injected directly into the tumor using a syringe. From the next day after the I cell and cell therapeutic agent injection, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. The tumor volume was measured in the same manner as in Example 2.2, and the measured tumor volume change was shown in FIG. 8B.

[0086] As shown in B of FIG. 8, the tumor volume was more effectively decreased in the experimental group treated with the cell therapeutic agent, confirming that the cell therapeutic agent had more excellent anti-cancer effect than the I cell, and had excellent therapeutic effect in the lung cancer subcutaneous tumor model (*, p < 0.05 upon comparison with the PBS group).

2.5. Anti-cancer effect of cell therapeutic agenton colon cancer

[0087] 5X10⁶ HT29 colon cancer cells (ATCC No.HTB-38™) were suspended in 100 µl of a phosphate buffer solution containing 20% Matrigel (BD), and transplanted subcutaneously in 7-week-old immunodeficient nude mice (Balb/c nude). After the transplantation, when the tumor size reached 40 to 100 mm³, the I cells and the cell therapeutic agent prepared in Preparation Example 2 were injected. More specifically, the I cells and cell therapeutic agent prepared in Preparation Example 2 were suspended in the phosphate buffer solution, followed by centrifugation at 500 x g for 5 minutes.

[0088] This procedure was repeated twice, and then the I cells or the cell therapeutic agent were prepared to have concentration of 1 x 10⁶/100 µl in the phosphate buffer solution and injected directly into the tumor using a syringe. From the next day after the I cell and cell therapeutic agent injection, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. The tumor volume was measured in the same manner as in Example 2.2, and the measured tumor volume change was shown in FIG. 8C.

[0089] As shown in C of FIG. 8, the tumor volume was more effectively decreased in the experimental group treated with the cell therapeutic agent, confirming that the cell therapeutic agent had more excellent anti-cancer effect than the I cell, and had excellent therapeutic effect in the colon cancer subcutaneous tumor model (*, p < 0.05 upon comparison with the PBS group, and #, p < 0.05 upon comparison with the I cell group).

[0090] From the above results, it was confirmed that the cell therapeutic agent had an excellent anti-cancer effect in various types of cancer such as brain tumor, liver cancer, lung cancer, colon cancer, and exhibited a more excellent anti-cancer effect in all types of cancer as compared to the I cell.

Example 3. Synergistic effect of combination therapy of cell therapeutic agent (in vitro)

3.1 In vitro combination therapy with temozolomide

[0091] 10,000 GFP-expressing U87MG (Korean Cell Line Bank KCLBNo.30014) glioma cells and cell therapeutic agent of 10,000 F cells or mesenchymal stem cells (MSCs) were cultured in a 12-well plate. The next day, the cells were treated with temozolomide (TMZ) at a concentration of 0 to 1000 µM and the prodrug 5-FC at a concentration of 0 to 1,000 µM, and replaced with a new medium containing the drug once every two days, and after 6 days, the cells were obtained. A schematic diagram of this experiment is shown in A of FIG. 9. Fluorescence images of U87MG expressing GFP remaining in the whole well were taken using a dissecting fluorescence microscope (Olympus), and cell death was confirmed. The results are shown in D of FIG. 9.

[0092] As shown in D of FIG. 9, it was confirmed that the fluorescence expression was decreased according to an increase in the temozolomide treatment concentration and an increase in the 5-FC treatment concentration, and the bystander effect of the cell therapeutic agent was elevated by the combined administration with temozolomide.

[0093] After the fluorescence images were taken, 200 µl of 1x passive lysis buffer (Promega) was added, and the cells were placed on ice for 10 minutes. The cell lysate was transferred to an E-tube and centrifuged at 12,000 rpm for 5 minutes, and the supernatant was transferred to a new container. 100 µl of the supernatant was transferred to a black 96-well plate, and the intensity of fluorescence was measured under conditions of excitation 488 nm and emission 530 nm using a fluorimeter (GEMINI EM, molecular device) (B and C of FIG. 9). The actual IC₅₀ values obtained by treating the two types of anti-cancer agents together were expressed as isobologram. The solid line connecting the IC₅₀ values when the anti-cancer agent was treated alone in the isobologram is a theoretical additive line, which means that when the values obtained by simultaneously treating two anti-cancer agents are on the solid line, there is simply an additive effect. On the other hand, it means that when the value is lower than the solid line, there is a synergistic effect, and conversely, when the value is above the solid line, there is an antagonistic effect. The results are shown in FIG. 9E.

[0094] As shown in E of FIG. 9, all of the marked points when the MSC/CD was treated with 5-FC and temozolomide in combination were present at the lower side as compared to the IC₅₀ values when the anti-cancer agent was treated alone, which was confirmed that there was a synergistic effect which is more excellent than the additive effect obtained by simple treatment with the two anti-cancer agents together.

3.2 In vitro combination therapy with Carmustine (BCNU)

[0095] 10,000 GFP-expressing U87MG glioma cells, i.e., U87/GFP (Korean Cell Line Bank KCLBNo.30014) and cell therapeutic agent of 10,000 F cells (MSC/CD) were cultured in a 12-well plate. From the next day, the cells were treated with Carmustine (BCNU, Sigma) at a concentration of 0 to 300 µM and the prodrug 5-FC at a concentration of 0 to 300 µM, and cultured for 6 days while replacing with a new medium containing the drug once every two days. On the 7^th day, the culture solution was removed, 200 µl of 1X passive lysis buffer (Promega) was then added to each well, and each well was allowed to stand at 4°C for 10 minutes. The cell lysate was collected and centrifuged at 12,000 rpm for 5 minutes to obtain a supernatant. 100 µl of the supernatant was transferred to a black 96-well plate in which light is blocked, and the intensity of fluorescence was measured under conditions of excitation 488 nm and emission 530 nm using a fluorimeter (GEMINI EM, molecular device). A schematic diagram of this experiment is shown in A of FIG. 10.

[0096] The actual IC₅₀ values obtained by treatment with the two types of anti-cancer agents together were expressed as isobologram, and the results were shown in FIG. 10B.

[0097] As shown in B of FIG. 10, all of the marked points when U87/GFP was treated with [cell therapeutic agent (MSC/CD) + 5-FC] and carmustine in combination were present at the lower side of the solid line as compared to the IC₅₀ values when the anti-cancer agent was treated alone, which was confirmed that there was a synergistic effect which is more excellent than the additive effect obtained by simple treatment with the two anti-cancer agents together.

3.3 In vitro combination therapy with Irinotecan

[0098] 10,000 U87/GFP and cell therapeutic agent of 10,000 F cells (MSC/CD) were cultured in a 12-well plate. From the next day, the cells were treated with Irinotecan (Sigma) at a concentration of 0 to 30 µM and the prodrug 5-FC at a concentration of 0 to 300 µM, and cultured for 6 days while replacing with a new medium containing the drug once every two days. On the 7th day, the culture solution was removed, 200 µl of 1X passive lysis buffer was then added to each well, and each well was allowed to stand at 4°C for 10 minutes. The cell lysate was collected and centrifuged at 12,000 rpm for 5 minutes to obtain supernatant. 100 µl of the supernatant was transferred to a black 96-well plate in which light is blocked, and the intensity of fluorescence was measured under conditions of excitation 488 nm and emission 530 nm using a fluorimeter (GEMINI EM). The actual IC₅₀ values obtained by treatment with the two types of anti-cancer agents together were expressed as isobologram, and the results were shown in C of FIG. 10.

[0099] As shown in C of FIG. 10, the IC₅₀ values obtained by treatment with irinotecan alone in the isobologram was 3.2 µM and the IC₅₀ values obtained by treatment with 5-FC was 73.6 µM, and these IC₅₀ values were connected to obtain a theoretical additive line representing a simple additive effect. The IC₅₀ values obtained when U87/GFP was treated with [cell therapeutic agent (MSC/CD) + 5-FC] and irinotecan in combination were present at the lower side of the solid line as compared to the IC₅₀ values when the anti-cancer agent was treated alone, which was confirmed that there was a synergistic effect which is more excellent than the effect obtained by simple treatment with the two anti-cancer agents together.

[0100] Since all of temozolomide, carmustine, and irinotecan are known as anti-cancer agents that act on proliferating cells, if they affect the survival of not only U87/GFP cells but also proliferating cell therapeutic agent, the anti-cancer effect of [cell therapeutic agent (MSC/CD) + 5-FC] might be reduced. However, contrary to the expectation, it was confirmed from E of FIG. 9 that the synergistic effect could be obtained which was rather elevated as compared to the administration of the anti-cancer agent alone or in combination, when [cell therapeutic agent (MSC/CD) + 5-FC] was used in combination with temozolomide. That is, the synergistic effect is an unexpected effect that is not capable of being expected in the existing combination therapies.

3.4 In vivo combination therapy with temozolomide

[0101] The synergistic effects confirmed in the above-descriptions of 3.1 to 3.3 were further confirmed and verified in vivo. On the 6^th days after transplantation of U87MG glioma cells expressing LacZ, the cell therapeutic agent prepared in Preparation Example 2 were suspended in a Plasma Solution A, followed by centrifugation at 500 x g for 5 minutes. The supernatant was discarded, and the washing procedure was repeated twice. Then, the cell suspension was prepared to have a concentration of 3 x 10⁵/6µl. The cell suspension was transplanted at a rate of 0.3 µl/min at the brain coordinates of AP = +0.5 mm, ML = - 1.8 mm, and DV = -3 mm. From the next day after the cell transplantation, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. After 4 days, temozolomide (1 mg/ml in DMSO : physiological saline = 1 : 1) was intraperitoneally injected at a dose of 5 mg/kg for 5 days. On 28^th day, brain tissues were obtained from 8 animals in each animal group and X-gal staining was performed in the same manner as in Example 2 to measure the size of brain tumor. The experimental procedure is shown in A of FIG. 11, and the changes in measured brain tumor size are shown in B and C of FIG. 11.

[0102] As shown in B and C of FIG. 11, the average size of vehicle control tumors was 59.8 mm³, whereas the average size of the animal group into which the cell therapeutic agent were transplanted was 11.8 mm³, the average size of the animal group treated with temozolomide alone was 9.9 mm³, and the average size of the animal group into which the cell therapeutic agent + temozolomide were transplanted was 2.7 mm³. The animal group into which the cell therapeutic agent and temozolomide combination therapy were transplanted had the most reduced average size of the tumor, and showed the most excellent anti-cancer effect.

[0103] In addition, the survival rate according to the treatment of brain tumor was measured up to 90 days, and the results were compared in each experimental group and showed in D of FIG. 11.

[0104] As shown in D of FIG. 11, the median survival in the control group was 32 days, but prolonged to 42 days in the cell therapeutic agent treatment group and 42 days in the temozolomide treatment group. In particular, the median survival was prolonged to 70 days in the group with the F cell and temozolomide combination therapy, and a remarkable improvement in the survival rate was observed even in comparison with the group treated with the anti-cancer agent alone as well as the control group.

[0105] This suggests that the combination therapy with F cell showed a remarkably excellent effect even in the combination therapy with the existing anti-cancer agents, and thus, the combination therapy with F cell is able to be utilized as a remedy for improving the existing chemotherapy.

Example 4. Subcutaneous tumor treatment effect of F cells

[0106] To determine whether the cell therapeutic agent could exhibit the anti-cancer effect in tumors other than brain tumor, U87MG glioma cells were transplanted into subcutaneous tissue to construct a non-brain cancer model. 1 x 10⁶ U87MG glioma cells were suspended in 100 µl of a phosphate buffer solution containing 20% Matrigel (BD), and transplanted subcutaneously in 7-week-old immunodeficient nude mice. The size of the tumor was measured twice weekly using a digital caliper, and the tumor volume was calculated using the following Equation.

[0107] When the size of the tumor reached 30 mm³ or more on 20^th day after the U87MG glioma cells were transplanted into the subcutaneous tissue, the I cells and F cells prepared in Preparation Example 2 were suspended in a Plasma Solution A, and centrifuged at 500 x g for 5 minutes. This procedure was repeated twice, and then the I cells or the cell therapeutic agent were prepared to have concentration of 1 x 10⁶/100 µl F cells in the Plasma Solution A and injected directly into the tumor using a syringe. From the next day after the I cell and cell therapeutic agent injection, 5-FC (15 mg/ml physiological saline) was intraperitoneally injected at a dose of 500 mg/kg for one week. After one week from the administration of 5-FC was discontinued, temozolomide (Sigma-Aldrich) was intraperitoneally injected at a dose of 5 mg/kg for 5 days. Such an experimental method is briefly shown in A of FIG. 12. The measured tumor volume change is shown in B of FIG. 12. The Kaplan Meier survival graph obtained by measuring the lifespan of nude mice in the subcutaneous tumor model is shown in C of FIG. 12.

[0108] As shown in B of FIG. 12, it was confirmed that the tumor volume was more effectively decreased in the experimental group treated with cell therapeutic agent until the 11^th day before the administration of temozolomide, and the cell therapeutic agent showed more excellent anti-cancer effect than the I cells. Further, on the 21^st day after the administration of temozolomide, the tumor volume inhibitory effect in the cell therapeutic agent treatment group was confirmed to be very remarkable as compared to the non-treatment group (the control group) and the I cell treatment group. In addition, as shown in C of FIG. 12, the median survival of the control group was 23 days, and the median survival of the I cell treatment group was 30 days, whereas the cell therapeutic agent treatment group showed the median survival of 58 days, and thus, the life extension effect was also the greatest in the animal group treated with the cell therapeutic agent. Therefore, it may be appreciated that the cell therapeutic agent have excellent therapeutic effect in the subcutaneous tumor model, and in particular, exhibit a synergistic therapeutic effect through combination therapy with temozolomide, which demonstrates superiority of the cell therapeutic agent combination therapy in other organs, which is diffiult to be expected from in vitro experiment alone.

Claims

1. A method for preparing cell therapeutic agent comprising:

1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD) and then culturing;

2) freezing the cultured MSC/CD to prepare frozen MSC/CD; and

3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent,

wherein the MSC/CD is not subjected to cell culturing after freezing and thawing.

2. Cell therapeutic agent for use in preventing or treating cancer comprising:

administering the cell therapeutic agent to a subject in need of treatment; and administering 5-fluorocytosine (5-FC) to a subject in need of treatment,

wherein the cell therapeutic agent is prepared according to claim 1, comprising:

1) introducing cytosine deaminase (CD) into a mesenchymal stem cell (MSC) to prepare mesenchymal stem cell/cytosine deaminase (MSC/CD) and then culturing;

2) freezing the cultured MSC/CD to prepare frozen MSC/CD; and

3) thawing and suspending the frozen MSC/CD to prepare cell therapeutic agent, wherein the MSC/CD is not subjected to cell culturing after freezing and thawing.

3. The cell therapeutic agent for use according to claim 2, further comprising administering an anti-cancer agent to a subject in need of treatment.

4. The cell therapeutic agent for use according to claim 2, further comprising administering an anti-cancer agent to a subject in need of treatment before administration of the cell therapeutic agent or simultaneously with administration of the cell therapeutic agent.

5. The cell therapeutic agent for use according to claim 3, wherein the anti-cancer agent is at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, elotinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, sorafenib, bevacizumab, cetuximab, viscum album, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tiuxetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazine, alprostadil, holmium nitrate chitosan, gemcitabine, doxifluridine, pemetrexed, tegafur, capecitabine, gimeracil, oteracil, azacytidine, cytarabine, fludarabine, enocitabine, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, belotecan, topotecan, vinorelbine, etoposide, vincristine, vinblastine, tenifocide, idarubicin, epirubicin, mitoxantrone, mitomycin, bleomycin, daunorubicin, dactinomycin, pirarubicin, aclarubicin, pepromycin, temozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altretamine, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, taxotere, gleevec, taxol, herceptin, tarceva, avastin, zoladex, adriamycin, irinotecan, 10058-F4, cisplatin, cyclophosphamid, nitrosourea-based anti-cancer agent, methotrexate, carmustine (BCNU), lomustine (CCNU), and doxorubicin.

6. The cell therapeutic agent for use according to claim 2, wherein the cell therapeutic agent and the 5-fluorocytosine are administered simultaneously or sequentially.

7. The cell therapeutic agent for use according to claim 3, wherein the 5-fluorocytosine and the anti-cancer agent are administered simultaneously or sequentially.

8. The cell therapeutic agent for use according to claim 3, wherein the administration of the cell therapeutic agent is repeated with a cycle of 10 to 30 days.

9. The cell therapeutic agent for use according to claim 2, wherein the cancer is at least one selected from the group consisting of squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung cancer, peritoneal cancer, colorectal cancer, biliary tumor, nasopharyngeal cancer, laryngeal cancer, bronchial cancer, oral cancer, osteosarcoma, gallbladder cancer, kidney cancer, leukemia, bladder cancer, melanoma, brain cancer, glioma, brain tumor, skin cancer, pancreatic cancer, breast cancer, liver cancer, bone cancer, esophageal cancer, colon cancer, gastric cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck cancer, and rectal cancer.

Ansprüche

1. Verfahren zur Herstellung eines Zelltherapeutikums, umfassend:

1) Einführen von Cytosin-Deaminase (CD) in eine mesenchymale Stammzelle (MSC) zur Herstellung einer mesenchymalen Stammzelle/Cytosin-Deaminase (MSC/CD) und dann Kultivieren;

2) Gefrierenlassen des kultivierten MSC/CD zur Herstellung von gefrorenem MSC/CD; und

3) Auftauen und Suspendieren des gefrorenen MSC/CD zur Herstellung eines Zelltherapeutikums;

wobei das MSC/CD nach dem Gefrierenlassen und Auftauen keiner Zellkultur mehr unterzogen wird.

2. Zelltherapeutikum zur Verwendung bei der Prävention oder Behandlung von Krebs, umfassend:

Verabreichen des Zelltherapeutikums an einen Patienten, der einer solchen Behandlung bedarf; und Verabreichen von 5-Fluorcytosin (5-FC) an einen Patienten, der einer solchen Behandlung bedarf;

wobei das Zelltherapeutikum gemäß Anspruch 1 hergestellt wird, umfassend:

1) Einführen von Cytosin-Deaminase (CD) in eine mesenchymale Stammzelle (MSC) zur Herstellung einer mesenchymalen Stammzelle/Cytosin-Deaminase (MSC/CD) und dann Kultivieren;

2) Gefrierenlassen des kultivierten MSC/CD zur Herstellung von gefrorenem MSC/CD; und

3) Auftauen und Suspendieren des gefrorenen MSC/CD zur Herstellung eines Zelltherapeutikums, wobei das MSC/CD nach dem Gefrierenlassen und Auftauen keiner Zellkultur mehr unterzogen wird.

3. Zelltherapeutikum zur Verwendung gemäß Anspruch 2, weiterhin umfassend das Verabreichen eines Antikrebsmittels an einen Patienten, der einer solchen Behandlung bedarf.

4. Zelltherapeutikum zur Verwendung gemäß Anspruch 2, weiterhin umfassend das Verabreichen eines Antikrebsmittels an einen Patienten, der einer solchen Behandlung bedarf, vor der Verabreichung des Zelltherapeutikums oder gleichzeitig mit der Verabreichung des Zelltherapeutikums.

5. Zelltherapeutikum zur Verwendung gemäß Anspruch 3, wobei das Antikrebsmittel wenigstens eines ist, das aus der Gruppe ausgewählt ist, die aus Stickstofflost, Imatinib, Oxaliplatin, Rituximab, Elotinib, Trastuzumab, Gefitinib, Bortezomib, Sunitinib, Carboplatin, Sorafenib, Bevacizumab, Cetuximab, Viscum album, Asparaginase, Tretinoin, Hydroxycarbamid, Dasatinib, Estramustin, Gemtuzumab-Ozogamicin, Ibritumomab-Tiuxetan, Heptaplatin, Methylaminolävulinsäure, Amsacrin, Alemtuzumab, Procarbazin, Alprostadil, Holmiumnitrat-Chitosan, Gemcitabin, Doxifluridin, Bemetrexed, Tegafur, Capecitabin, Gimeracil, Oteracil, Azacytidin, Cytarabin, Fludarabin, Enocitabin, Decitabin, Mercaptopurin, Thioguanin, Cladribin, Carmofur, Raltitrexed, Docetaxel, Paclitaxel, Belotecan, Topotecan, Vinorelbin, Etoposid, Vincristin, Vinblastin, Tenifocid, Idarubicin, Epirubicin, Mitoxantron, Mitomycin, Bleomycin, Daunorubicin, Dactinomycin, Pirarubicin, Aclarubicin, Pepromycin, Temozolomid, Busulfan, Ifosfamid, Cyclophosphamid, Melphalan, Altretamin, Dacarbazin, Thiotepa, Nimustin, Chlorambucil, Mitolactol, Taxotere, Gleevec, Taxol, Herceptin, Tarceva, Avastin, Zoladex, Adriamycin, Irinotecan, 10058-F4, Cisplatin, Cyclophosphamid, Antikrebsmitteln auf Nitrosoharnstoff, Methotrexat, Carmustin (BCNU), Lomustin (CCNU) und Doxorubicin besteht.

6. Zelltherapeutikum zur Verwendung gemäß Anspruch 2, wobei das Zelltherapeutikum und das 5-Fluorcytosin gleichzeitig oder nacheinander verabreicht werden.

7. Zelltherapeutikum zur Verwendung gemäß Anspruch 3, wobei das 5-Fluorcytosin und das Zelltherapeutikum gleichzeitig oder nacheinander verabreicht werden.

8. Zelltherapeutikum zur Verwendung gemäß Anspruch 3, wobei die Verabreichung des Zelltherapeutikums mit einem Zyklus von 10 bis 30 Tagen wiederholt wird.

9. Zelltherapeutikum zur Verwendung gemäß Anspruch 2, wobei die Krebserkrankung wenigstens eine ist, die aus der Gruppe ausgewählt ist, die aus einem Plattenepithelkarzinom, kleinzelligem Lungenkrebs, nichtkleinzelligem Lungenkrebs, Lungenkrebs, Bauchfellkarzinom, Kolorektalkarzinom, biliärem Tumor, Nasopharyngealkarzinom, Laryngealkarzinom, Bronchialkrebs, Mundkrebs, Osteosarkom, Gallenblasenkrebs, Nierenkrebs, Leukämie, Blasenkrebs, Melanom, Gehirnkrebs, Gliom, Gehirntumor, Hautkrebs, Pankreaskarzinom, Brustkrebs, Leberkrebs, Knochenkrebs, Speiseröhrenkrebs, Kolonkarzinom, Magenkrebs, Gebärmutterhalskrebs, Prostatakrebs, Eierstockkrebs, Kopf-Hals-Karzinom und Rektalkarzinom besteht.

Revendications

1. Procédé pour préparer un agent thérapeutique cellulaire, comprenant les étapes consistant à :

1) introduire de la cytosine désaminase (CD) dans une cellule souche mésenchymale (MSC) pour préparer une cellule souche mésenchymale/cytosine désaminase (MSC/CD), et ensuite cultiver celle-ci,

2) faire congeler la MSC/CD cultivée pour préparer une MSC/CD congelée, et

3) décongeler et suspendre la MSC/CD congelée pour préparer un agent thérapeutique cellulaire,

dans lequel la MSC/CD n'est pas soumise à une culture cellulaire après la congélation et la décongélation.

2. Agent thérapeutique cellulaire à utiliser dans la prévention ou le traitement de cancer, comprenant :

administrer ledit agent thérapeutique cellulaire à un sujet nécessitant un traitement, et administrer de la 5-fluorocytosine (5-FC) à un sujet nécessitant un traitement,

dans lequel ledit agent thérapeutique cellulaire est préparé selon la revendication 1, comprenant :

1) introduire de la cytosine désaminase (CD) dans une cellule souche mésenchymale (MSC) pour préparer une cellule souche mésenchymale/cytosine désaminase (MSC/CD), et ensuite cultiver celle-ci,

2) faire congeler la MSC/CD cultivée pour préparer une MSC/CD congelée, et

3) décongeler et suspendre la MSC/CD congelée pour préparer un agent thérapeutique cellulaire, dans lequel la MSC/CD n'est pas soumise à une culture cellulaire après la congélation et la décongélation.

3. Agent thérapeutique cellulaire à utiliser selon la revendication 2, comprenant en outre l'administration d'un agent anticancer à un sujet nécessitant un traitement.

4. Agent thérapeutique cellulaire à utiliser selon la revendication 2, comprenant en outre l'administration d'un agent anticancer à un sujet nécessitant un traitement avant l'administration de l'agent thérapeutique cellulaire ou simultanément avec l'administration de l'agent thérapeutique cellulaire.

5. Agent thérapeutique cellulaire à utiliser selon la revendication 3, dans lequel ledit agent anticancer est au moins un choisi parmi le groupe consistant en moutarde azotée, imatinib, oxaliplatine, rituximab, élotinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatine, sorafénib, bévacizumab, cétuximab, Viscum album, asparaginase, trétinoïne, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicine, ibritumomab tiuxétane, heptaplatine, acide méthylaminolévulinique, amsacrine, alemtuzumab, procarbazine, alprostadil, nitrate d'holmium/chitosane, gemcitabine, doxifluridine, pémétrexed, tégafur, capécitabine, giméracil, otéracil, azacitidine, cytarabine, fludarabine, énocitabine, décitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docétaxel, paclitaxel, bélotécan, topotécan, vinorelbine, étoposide, vincristine, vinblastine, ténifocide, idarubicine, épirubicine, mitoxantrone, mitomycine, bléomycine, daunorubicine, dactinomycine, pirarubicine, aclarubicine, pépromycine, témozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altrétamine, dacarbazine, thiotépa, nimustine, chlorambucil, mitolactol, taxotère, Gleevec, taxol, Herceptine, tarcéva, avastine, zoladex, adriamycine, irinotécane, 10058-F4, cisplatine, cyclophosphamide, agent anticancer à base de nitrosourée, méthotrexate, carmustine (BCNU), lomustine (CCNU), et doxorubicine.

6. Agent thérapeutique cellulaire à utiliser selon la revendication 2, dans lequel ledit agent thérapeutique cellulaire et ledit 5-fluorocytosine sont administrés simultanément ou séquentiellement.

7. Agent thérapeutique cellulaire à utiliser selon la revendication 3, dans lequel ledit 5-fluorocytosine et ledit agent thérapeutique cellulaire sont administrés simultanément ou séquentiellement.

8. Agent thérapeutique cellulaire à utiliser selon la revendication 3, dans lequel l'administration dudit agent thérapeutique cellulaire est répétée avec un cycle de 10 à 30 jours.

9. Agent thérapeutique cellulaire à utiliser selon la revendication 3, dans lequel ledit cancer est au moins un choisi dans le groupe consistant en carcinome épidermoïde, cancer du poumon à petites cellules, cancer du poumon non à petites cellules, cancer du poumon, cancer péritonéal, cancer colorectal, tumeur biliaire, carcinome du nasopharynx, carcinome du larynx, cancer bronchique, cancer buccal, ostéosarcome, carcinome de la vésicule biliaire, cancer du rein, leucémie, cancer de la vessie, mélanome, cancer du cerveau, gliome, tumeur du cerveau, cancer de la peau, cancer du pancréas, cancer du sein, cancer du foie, cancer des os, cancer œsophagien, cancer du côlon, cancer de l'estomac, cancer du col de l'utérus, cancer de la prostate, cancer des ovaires, cancer de la tête et du cou, et cancer du rectum.

Drawing